Janux Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Janux Therapeutics, Inc. (Nasdaq: JANX) on September 9, 2021, reporting events that occurred on September 7, 2021. The Company is a Delaware corporation headquartered in La Jolla, California, and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance and director compensation arrangements.
Material Changes
The Board of Directors appointed two new members to the Board of Directors:
- Ronald Barrett, Ph.D.: Appointed as a Class I director with a term expiring at the 2022 annual meeting of stockholders.
- Alana McNulty: Appointed as a Class II director with a term expiring at the 2023 annual meeting of stockholders.
There are no reported transactions in which the new directors have an interest requiring disclosure under Item 404(a) of Regulation S-K.
Compensation and Governance Details
Pursuant to the Company's compensation policy for non-employee directors, the following arrangements were established for Dr. Barrett and Ms. McNulty:
- Cash Retainer: An annual cash retainer of $40,000 for Board service. For 2021, this amount is pro-rated based on the appointment date.
- Initial Option Grant: An option to purchase 30,000 shares of common stock granted on the effective date of appointment. These options vest monthly over a three-year period.
- Future Annual Grants: Automatic annual option grants to purchase 12,500 shares on the date of each annual meeting of stockholders. These vest in equal monthly installments over 12 months following the grant date, provided the director remains in service.
- Change in Control: All option grants vest in full upon a change in control, provided the director remains in continuous service immediately prior to such event.
- Indemnification: Both directors have entered into the Company's standard form of Indemnity Agreement.
Investor Verification Checklist
- Verify the pro-rated cash retainer calculation for 2021 based on the September 7 appointment date.
- Confirm the total number of shares authorized under the 2021 Equity Incentive Plan to ensure sufficient capacity for the new grants.
- Review the vesting schedule details for the initial 30,000-share grants to confirm the three-year monthly vesting timeline.
- Check for any subsequent filings regarding the 2022 and 2023 annual meetings to confirm the terms of future automatic grants.